Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Coherus Biosciences and keeping the price target at $4.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy’s rating is based on Coherus Biosciences’ promising advancements in their oncology pipeline, particularly with their selective anti-CCR8 antibody, CHS-114. This candidate is notable for its high specificity in targeting CCR8, a receptor involved in the tumor microenvironment, which is crucial for overcoming immune suppression in cancer therapies. The company’s strategic focus on oncology, combined with a strong cash position, provides a solid foundation for future growth.
Furthermore, Coherus is set to reveal multiple data readouts in 2026, which are anticipated to be significant catalysts for the stock. The ongoing trials, including those for CHS-114 in various cancer types, are expected to yield important results that could enhance the company’s market position. These factors, along with the validation from major industry players investing in similar targets, underpin McCarthy’s optimistic outlook and Buy rating for Coherus Biosciences.